magnolol has been researched along with Neurodegenerative Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; Fang, Y; Jia, R; Kang, X; Zhao, R; Zhu, G | 1 |
| Jia, J; Wang, X | 1 |
| Akae, H; Akagi, M; Akagi, R; Fukuishi, N; Fukuyama, Y; Hirashima, N; Matsui, N | 1 |
1 review(s) available for magnolol and Neurodegenerative Diseases
| Article | Year |
|---|---|
Nonpeptide neurotrophic agents useful in the treatment of neurodegenerative diseases such as Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biphenyl Compounds; Cells, Cultured; Dietary Supplements; Hippocampus; Humans; Lignans; Magnolia; Mice; Molecular Weight; Nerve Growth Factors; Neurodegenerative Diseases; Neurogenesis; Phytotherapy; Polyphenols; Rats; Structure-Activity Relationship; Zingiberales | 2015 |
2 other study(ies) available for magnolol and Neurodegenerative Diseases
| Article | Year |
|---|---|
Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Biphenyl Compounds; Humans; Lignans; Neurodegenerative Diseases; Neurons; Receptor, Muscarinic M1 | 2022 |
Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Autophagy; Cognitive Dysfunction; Mammals; Mice; Mice, Transgenic; Neurodegenerative Diseases; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases | 2023 |